Blog

Job – Scientific Affairs Manager – Swisse

Scientific Affairs Manager APPLY NOW Job no: Project Courage Job Code RD 02 Work type: Full time Location: Victoria Longing for a career, not a job, working with a team of people who are dedicated to creating premium quality, scientifically validated…

Australia’s clean, green & healthy image underpins surging Chinese investment in Australian healthcare

Doug Ferguson, KPMG’s National Managing Partner Asia & International Markets, discusses the latest trends from KPMG’s Demystifying Chinese Investment in Australian Healthcare report. Chinese investment in Australian healthcare companies has surged over the past three years. AUD5.5 billion has flowed…

Australia 2030: Prosperity through Innovation – Innovation and Science Australia’s strategic plan for Australia’s innovation future release

Innovation and Science Australia (ISA) has challenged Australians, and their governments, to be bolder in using innovation to unlock economic and social opportunity for the future. The call came as ISA Chair, Mr Bill Ferris AC, launched Australia…

2017 – A Big Year for Biotech!

Our vision for Victoria is to lead the world in health innovation. Discovering, developing and manufacturing the health technologies that change the world. New drugs, devices, diagnostics, vaccines, therapies and digital products – Victoria is the best place to…

Major $640 million investment in Australia’s world-leading medical research

The Turnbull Government will invest $640 million to support Australia’s world-leading health and medical researchers as they continue their work in the laboratory, clinic and the community to find the next major medical breakthrough. Cancer research continues to…

$33 million for CRC Projects to tackle diverse industry problems 

http://minister.industry.gov.au/ministers/laundy/media-releases/33-million-crc-projects-tackle-diverse-industry-problems?mc_cid=da234fdd4a&mc_eid=1eb046c0f3 Better barramundi breeding, disease resistant bananas, a portable brain scanner for early stroke detection and a process to turn waste plastics into spectacle frames are amongst 15 highly diverse industry-led projects to receive a $33 million investment…

Job: Senior Quality Assurance Manager

• TGA Licensed Manufacturer • Manage department of 38+ staff • Winner of multiple export awards Our Client Our client is an Australian success story experiencing year on year international growth in over 22 countries. Their mission is…

$2.5M GRANT AWARDED TO ADVANCE WOUNDVUE™ DEVELOPMENT

• Joint collaboration with University of Melbourne and Planet Innovation Adelaide, Australia, 7 December 2017: Australian medical technology company, LBT Innovations Limited (ASX:LBT) is pleased to announce it has been awarded a $2.513 million grant to advance the…

Phosphagenics Signs a Multinational License for TPM® in Personal Care Products

Phosphagenics Signs a Multinational License for TPM® in Personal Care Products 4 December 2017, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce the signing of a non-exclusive license agreement with Rodan…

Media Release – Industry calls for Medical Technologies and Pharmaceuticals Innovation Hub

Media Release – Monday 20th November 2017 At its Annual General Meeting today, BioMelbourne Network will launch a pre-budget submission calling for the Victorian Government to invest in a Medical Technologies and Pharmaceuticals Innovation Hub in Melbourne. The Hub…

Advertise your job here

BioMelbourne Network member organisations can advertise their job opportunity here by emailing them to info@biomelbourne.org.  Our website receives more than 12,000 unique visitors per month We will also send your job opportunity to the 4,500+ recipients of our…

Prima BioMed has just announced new clinical data from its TACTI-mel Phase I trial in Australia – which is investigating Prima’s lead drug, IMP321, in combination with KEYTRUDA in metastatic melanoma

Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead…

Home

News & opinion

Member Directory

Events